October 7, 2019
Proteus Digital Health’s ingestible pill and sensor system could improve medication adherence, and subsequently treatment, for patients with tuberculosis (TB), according to new data from an independent study conducted in California.
Published Friday in PLoS Medicine, the trial found Proteus’ system to accurately determine whether or not a medication was taken. Patients using the system at home...
January 17, 2019
In conjunction with Fairview Health Services and University of Minnesota Health, Proteus Digital Health unveiled plans to pair its sensor-equipped digital pills with an oral oncology therapeutic.
According to an announcement from Proteus, the new care model is currently being used to treat stage 3 and stage 4 colorectal cancer patients receiving care at Fairview. There, clinicians are prescribing...
October 15, 2018
Proteus Digital Health and Otsuka Pharmaceutical have expanded their partnership on digital therapeutics.
On Thursday, Proteus announced that it received $88 million from the pharma company, which will go toward the continued development and commercialization of its ingestible sensor pill platform. Additionally, the five-year deal will also support the investigation of a wider digital medicine...
October 10, 2018
Children’s Health, a Texas-based pediatric health system, is teaming up with Proteus to pilot a new program aimed at tackling adherence issues in pediatric heart transplant patients by inserting ingestible sensors into prescribed pills, which can track when the medication was taken.
The system is made up of a wearable patch worn by the patient and the sensor-infused pill. When the pill is broken...
August 30, 2018
Otsuka Pharmaceuticals and Proteus Digital Health’s sensor-carrying pill Abilify MyCite is on its way to US patients thanks to a new collaboration agreement between Otsuka and Magellan Health. Announced this morning by the pharmaceutical company, the rollout will initially be limited to give Otsuka and Magellan a better idea of how best to deploy the technology at scale.
“We are eager for...
July 26, 2018
Proteus Digital Health’ pitch to track adherence using sensor-equipped pills has found another audience in the HIV prevention community.
Among the featured data presented at this week’s International AIDS Conference in Amsterdam was a trial that outfitted Gilead Sciences’ preventive HIV drug Truvada (tenofovir/emtricitabine) with the tracking technology. Here, researchers found that the sensor-...
March 8, 2018
It’s still the early days, but the FDA’s approval of Proteus Digital Health and Otsuka Pharmaceuticals’ Abilify MyCite has changed the discussion of digital technology in healthcare. The first approval of drug delivery via a sensor-equipped pill sparked debates over the tradeoff of privacy for medication adherence, and whether these types of technologies would find a role in future healthcare....
November 21, 2017
Opioid adherence remains a hot topic in healthcare amidst the US ongoing epidemic, and a solution may lie within the pills themselves. In a study recently published in Anesthesia & Analgesia, researchers testing eTectRx’s digital pill technology could allow practitioners to better understand patient opioid adherence, thereby paving the way to more appropriate dosage and use of the drugs.